SIETES :: 93135 citas

Resultados de la búsqueda por COPAGO REFINAR BÚSQUEDA

1.

Dayoub EJ, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Giri J, Groeneveld PW. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008-2016. JAMA Intern Med 2018;178:julio. [Ref.ID 102882]

2.

Anónimo. Prescription charges for 2016. Prescribing Advice for GPs 2016:6 de mayo. [Ref.ID 100330]

3.

Walker J. Patients struggle with high drug prices. Out-of-pocket costs for pricey new drugs leave even some insured and relatively affluent patients with hard choices on how to afford them. Wall St J 2016:1. [Ref.ID 99949]

4.

Anónimo. Patients affected by jump in prices of generic medicines. DIA Daily 2014:9 de julio. [Ref.ID 97745]

5.

Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, Bustreo F, Evans D, Feachem RGA, Frenk J, Ghosh G, Goldie SJ, Gupta S, Horton R, Kruk ME, Mahmoud A, Mohohlo LK, Ncube M, Pablos-Mendez A, Reddy KS, Saxenian H, Soucat A, Ulltveit-Moe KH. Global health 2035: a world converging within a generation. Lancet 2013;382:1898-955. [Ref.ID 96314]

6.

Ross JS, Kesselheim AS. Prescription-drug coupons - No such thing as a free lunch. N Engl J Med 2013;369:1188-9. [Ref.ID 96300]

7.

van de Vooren K, Curto A, Garattini L. Optional copayments for anticancer drugs. BMJ 2013;346:19-21. [Ref.ID 94889]

8.

Choudhry NK, Fischer MA, Avorn JL, Lee JL, Schneeweiss S, Solomon DH, Berman C, Jan S, Lii J, Mahoney JJ, Shrank WH. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol 2012;60:1817-24. [Ref.ID 93132]

9.

Minué Lorenzo S, García Gutiérrez JF, Mercader-Casas JJ. Assault on universalism. Beginning of the end for Spain's national health system. BMJ 2012;344:29. [Ref.ID 92849]

10.

García Rada A. Spain introduces public health system based on employment status. BMJ 2012;344:6. [Ref.ID 92846]

11.

Benach J, Tarafa G, Muntaner C. El copago sanitario y la desigualdad: ciencia y política. Gaceta Sanitaria 2012;26:80-2. [Ref.ID 92166]

12.

Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M, Reisman L, Fernandes J, Spettell C, Lee JL, Levin R, Brennan T, Shrank WH, for the Post-Myocardial Infarction Free RX Event and Economic Evaluation (MI FREEE) Trial. Full coverage for preventive medications after myocardial infarction. N Engl J Med 2011;365:2088-97. [Ref.ID 91660]

13.

Fuchs VR. The doctor's dilemma — What Is “appropriate” care?. N Engl J Med 2011;365:585-7. [Ref.ID 91006]

14.

Angora Mazuecos F. Público/privado versus derecho/negocio en materia de salud. Revista Clínica de Medicina de Familia 2011;4:219-22. [Ref.ID 90666]

15.

Federación de Asociaciones para la Defensa de la Sanidad Pública. Doce propuestas para garantizar la sostenibilidad del Sistema Sanitario Público. Salud 2000 2011;24:5-11. [Ref.ID 90022]

16.

Shrank WH, Choudhry NK, Fischer MA, Avorn J, Powell M, Schneeweiss S, Liberman JN, Dollear T, Brennan TA, Brookhart MA. The epidemiology of prescriptions abandoned at the pharmacy. Ann Intern Med 2010;153:633-40. [Ref.ID 89657]

17.

Ceresuela Weissman E, Coll Benejam T, Gené Badia J, Magallón Botaya R, Morera Castell R, Sueiro Justel J. COPAGO Conclusiones desde la evidencia científica. Sociedad Española de Medicina Familiar y Comunitaria 2010:1-25. [Ref.ID 89447]

18.

Trivedi AN, Moloo H, Mor V. Increased ambulatory care copayments and hospitalizations among the eIderly. N Engl J Med 2010;362:320-8. [Ref.ID 88738]

19.

Coombes R. Giving private and NHS drugs separately will be hard, MPs say. BMJ 2009;338:1167. [Ref.ID 85893]

20.

Kmietowicz Z. Patients told they can combine private drugs with NHS care. BMJ 2008;337:1071. [Ref.ID 84500]